Trade Cyclerion Therapeutics, Inc. - CYCN CFD

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).